2m 2m 2m 2m 2m 2m 2m
- $1.7BMarket Cap
- -23.44%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
BAUSCH HEALTH (BHC)
Key Performance
More- Earnings Score: 30
- Momentum Score: 44
- True Yield: N/A
- Financial Health Score: 0
Latest Research & News
The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.
05/04/2026, 1:00 PM • GlobeNewswire
Why Bausch Health Companies Was Crawling Higher This Week
Bausch Health Companies reported Q1 2026 earnings that beat analyst expectations with $2.52 billion in revenue (up 12% YoY) and non-GAAP net income of $0.78 per share (up 35% YoY), exceeding consensus estimates of $2.42 billion and $0.68 per share respectively. The company maintained its full-year 2026 guidance and highlighted 12 consecutive quarters of revenue growth, driving the stock up nearly 2% for the week.
05/01/2026, 1:09 AM • The Motley Fool
The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.
04/20/2026, 1:00 PM • GlobeNewswire
The global dermatology devices market is projected to grow from $14.4 billion in 2024 to $25.6 billion by 2030, with a CAGR of 10.4%. Growth is driven by rising skin cancer incidence, aging populations, aesthetic procedure demand, and technological innovations including picosecond lasers and 3D bioprinting. North America leads with 52.3% market share.
04/13/2026, 1:21 PM • GlobeNewswire
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.
02/18/2026, 4:00 AM • GlobeNewswire
The Energy-Based Aesthetic Devices Market is projected to grow from USD 7.03 billion in 2025 to USD 11.80 billion by 2031 at a CAGR of 9.02%. Growth is driven by increased demand for hair removal treatments, med-spa expansion, minimally invasive procedures, and AI integration. Laser-based technology dominates the market, with North America leading globally. Key challenges include rising health and wellness awareness and high device costs.
02/17/2026, 4:58 AM • GlobeNewswire
The global ophthalmic drugs market is projected to grow from USD 37.35 billion in 2023 to USD 62.74 billion by 2032, driven by increasing eye disorders, advanced drug delivery methods, and rising healthcare awareness.
12/07/2025, 8:05 AM • GlobeNewswire
Why Bausch Health Companies Stock Rocketed 11% Higher Today
Bausch Health Companies' stock rose 11% after acquiring Wuhan Shibo Zhenmei Technology, a distributor of its aesthetic products in China, which enhances its market presence in the region.
12/01/2025, 7:02 PM • The Motley Fool
Biggest Stock Movers Today, Dec. 1: BHC, SMR, & More
Stock markets experienced a mixed day with major indexes declining, while individual stocks showed significant movements. Healthcare and technology stocks saw notable performance changes, with some companies experiencing substantial gains or losses.
12/01/2025, 4:34 PM • The Motley Fool
5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds
The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like user growth, economic recovery, and strategic improvements in their respective industries.
10/31/2025, 1:48 PM • Investing
5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds
The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like market overreactions, innovative strategies, and sector recovery.
10/31/2025, 11:32 AM • Investing
5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds
The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like technological innovation, market recovery, and strategic business improvements.
10/31/2025, 10:07 AM • Investing
5 Undervalued Stocks Under $10 Poised for Double-Digit Rebounds
An analysis of five stocks trading under $10 that show potential for significant price appreciation, highlighting their current challenges and future growth opportunities across social media, gaming, pharmaceuticals, fast food, and airline industries.
10/31/2025, 7:34 AM • Investing
Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners
Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.
09/10/2025, 11:30 PM • GlobeNewswire
Basal Cell Carcinoma Treatment Market to Reach USD 9.01 Billion by 2034, Reports Towards Healthcare
The global basal cell carcinoma treatment market is expected to grow from USD 3.33 billion in 2024 to USD 9.01 billion by 2034, with a CAGR of 10.48%. North America dominates the market, and technological advancements in treatment are driving market expansion.
09/09/2025, 10:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Key Executives
- Thomas J. Appio
- Jean-Jacques Charhon
- Seana Carson
- Aimee J. Lenar
- Steven Lee
Current Ownership Distribution
- Institutions4.8B (85.38%)
- Insiders440.1M (7.79%)
- Mutual Funds386.1M (6.83%)
- Other0 (0.00%)